Immunic

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immunic and other ETFs, options, and stocks.

About IMUX

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. 

CEO
Daniel Vitt
CEODaniel Vitt
Employees
92
Employees92
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2003
Founded2003
Employees
92
Employees92

IMUX Key Statistics

Market cap
134.58M
Market cap134.58M
Price-Earnings ratio
-1.29
Price-Earnings ratio-1.29
Dividend yield
Dividend yield
Average volume
383.73K
Average volume383.73K
High today
$10.24
High today$10.24
Low today
$9.66
Low today$9.66
Open price
$9.76
Open price$9.76
Volume
58.91K
Volume58.91K
52 Week high
$15.10
52 Week high$15.10
52 Week low
$5.06
52 Week low$5.06

Stock Snapshot

The current Immunic(IMUX) stock price is $9.88, with a market capitalization of 134.58M. The stock trades at a price-to-earnings (P/E) ratio of -1.29.

On 2026-05-04, Immunic(IMUX) stock traded between a low of $9.66 and a high of $10.24. Shares are currently priced at $9.88, which is +2.3% above the low and -3.5% below the high.

The Immunic(IMUX)'s current trading volume is 58.91K, compared to an average daily volume of 383.73K.

In the last year, Immunic(IMUX) shares hit a 52-week high of $15.10 and a 52-week low of $5.06.

In the last year, Immunic(IMUX) shares hit a 52-week high of $15.10 and a 52-week low of $5.06.

IMUX News

TipRanks 3h
Immunic initiated with an Outperform at LifeSci Capital

LifeSci Capital analyst Sam Slutsky initiated coverage of Immunic (IMUX) with an Outperform rating and $56 price target Unlock hedge fund-level data and powerf...

TipRanks 6d
Immunic Appoints Veteran Neurology Leader as Chief Medical Officer

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Nasdaq 6d
Immunic Appoints Michael Panzara As CMO

(RTTNews) - Immunic, Inc. (IMUX), Tuesday announced the appointment of Michael Panzara, as Chief Medical Officer, succeeding Andreas Muehler, effective April 24...

Immunic Appoints Michael Panzara As CMO

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own IMUX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.